Healthy
Conditions
Brief summary
A clinical study to measure the Safety, Tolerability, and Pharmacokinetics of OP-101 After Subcutaneous Administration in Healthy Volunteers
Interventions
DRUGOP-101
Subcutaneous injection of OP-101 in healthy volunteers
Sponsors
Orpheris, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Is a healthy man or woman age 18 to 65 years, inclusive, at the Screening Visit; * Has the ability to understand and sign the written Informed Consent Form (ICF) and local medical privacy authorization forms, which must be obtained prior to any study related procedures being completed; * Body mass index (BMI) between 18 and 32 kg/m2, inclusive; * Is in general good health, based upon the results of a medical history assessment, physical examination, vital signs, and laboratory profile, as judged by the Investigator; * Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone (FSH) in the postmenopausal range at screening, based on the central laboratory's ranges; * Female subjects of childbearing potential (ie, ovulating, premenopausal, and not surgically sterile) and all male subjects must use a medically accepted contraceptive regimen (including hormonal contraceptives) during their participation in the study and for 30 days after the last administration of study drug. Medically accepted contraceptive methods are defined as those with 90% or greater efficacy; * Acceptable methods of contraception for male subjects enrolled in the study include the following: • Condoms or surgical sterilization of subject at least 26 weeks before the Screening Visit (vasectomy); * Acceptable methods of contraception for female subjects enrolled in the study include the following: * Surgical sterilization of subject at least 26 weeks before the Screening Visit (includes hysterectomy or bilateral tubal ligation, oophorectomy, or salpingectomy); * Intrauterine device for at least 12 weeks before the Screening Visit; * Hormonal contraception (oral, implant, injection, ring, or patch) for at least 12 weeks before the Screening Visit; or * Diaphragm; * If male, subjects must agree to abstain from sperm donation through 90 days after administration of the last dose of study drug; * Female subjects may not be pregnant, lactating, or breastfeeding; * Female subjects of childbearing potential must have negative result for pregnancy test at screening and Check-in; * Subjects must have a negative test result for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCVab), and human immunodeficiency virus (HIV) antibody at screening; * Subjects must have an estimated glomerular filtration rate (eGFR) of ≥90 mL/min/1.73m2 at screening; * Subjects must have a negative urine test for drugs of abuse (opiates, benzodiazepines, amphetamines, cannabinoids, cocaine, barbiturates, and phencyclidine), cotinine, and breath alcohol test at screening and Check-in; and * Subjects must be willing and able to abide by all study requirements and restrictions.
Exclusion criteria
* Evidence of clinically significant hematologic, renal, endocrine, pulmonary, cardiac, gastrointestinal (GI), hepatic, psychiatric, neurologic, immunologic, allergic disease (including multiple or clinically significant drug allergies), or any other condition that, in the opinion of the Investigator, might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study; * History of malignancy (other than successfully treated basal cell or squamous cell skin cancer); * History or presence of an abnormal ECG that, in the opinion of the Investigator, is clinically significant; * Laboratory results (serum chemistry, hematology, coagulation, and urinalysis) outside the normal range at screening and Check-in and considered clinically significant in the opinion of the Investigator. Any elevation of aspartate transaminase (AST) and alanine transaminase (ALT) above the upper limit of normal at screening and/or Check-in is exclusionary. One retest of an exclusionary laboratory result is allowed at the discretion of the Investigator; * Has had an acute illness considered clinically significant by the Investigator within 30 days prior to screening; * History of alcoholism or drug abuse within 2 years prior to screening; * Has used any product containing nicotine within 90 days prior to screening or intends to use any product containing nicotine during the course of the study; * Has had any immunizations (live vaccines) in the 4 weeks prior to screening; * Has used medications that affect GI motility or gastric emptying; such as metoclopramide, proton pump inhibitors, and H2 blockers; within 30 days prior to Day 1; * Has used any prescription or over-the-counter medication (with exception of acetaminophen), vitamins/herbal supplements (with the exception of hormonal contraceptives) within 14 days prior to Day 1; * Has used any other study drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to Day 1; * Has lost or donated \>450 mL of whole blood or blood products within 30 days prior to screening; * Investigator has reason to believe that the subject may be unable to fulfill the protocol visit schedule or requirements; * Has any finding that, in the view of the Investigator or Medical Monitor, would compromise the subject's safety requirements; or * Is employed by the Sponsor, the Contract Research Organization (CRO), or the study site (permanent, temporary contract worker, or designee responsible for the conduct of the study), or is a family member (spouse, parent, sibling, or child) of the Sponsor, CRO, or study site employee.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events | Up to Day 15 | An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. A TEAE (treatment-emergent adverse event) was defined as an AE that emerges, having been absent prior to the study, or an AE that worsens in severity after the first dose of the study drug. Serious AE (SAE) was an AE resulting in any of the following outcomes: death; life-threatening adverse event, required hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, or a medically important event. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of OP-101 | Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose | Cmax: maximum observed plasma concentration. |
| Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of OP-101 | Pre-dose, 0.5 hours and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose | Tmax: time to reach maximum observed plasma concentration. |
| Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of OP-101 | Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose | AUC0-last: Area under the concentration versus time curve from time zero to the last quantifiable concentration (Clast). |
| Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to 48 Hour Post Dose Time Point (AUC0-48) of OP-101 | Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose | Area under the concentration versus time curve from time zero to 48 hour post dose time point. |
| Pharmacokinetics: Renal Clearance (CLR) for OP-101 | Pre-dose, 0 to 4, 4 to 8, 8 to 12, 12 to 18, 18 to 24, and 24 to 48 hours post dose | CLR was defined as renal clearance of the drug from plasma utilizing the AUC and cumulative amount of unchanged study drug excreted into the urine (Ae) to the same duration (as Amount recovered/AUC at 0-48 hours). |
Countries
Australia
Participant flow
Pre-assignment details
A total of 8 participants were enrolled and treated in the study.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: 4 mg/kg Participants in Cohort 1 received a single dose of 4 milligram per kg (mg/kg) OP-101 as subcutaneous (SC) injection on Day 1. | 4 |
| Cohort 2: 8 mg/kg Participants in Cohort 2 received a single dose of 8 mg/kg OP-101 as SC injection on Day 1. | 4 |
| Total | 8 |
Baseline characteristics
| Characteristic | Cohort 1: 4 mg/kg | Cohort 2: 8 mg/kg | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants | 4 Participants | 8 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 4 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Filipino | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 3 Participants | 3 Participants | 6 Participants |
| Sex: Female, Male Female | 3 Participants | 4 Participants | 7 Participants |
| Sex: Female, Male Male | 1 Participants | 0 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 0 / 4 |
| other Total, other adverse events | 2 / 4 | 3 / 4 |
| serious Total, serious adverse events | 0 / 4 | 0 / 4 |
Outcome results
Primary
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. A TEAE (treatment-emergent adverse event) was defined as an AE that emerges, having been absent prior to the study, or an AE that worsens in severity after the first dose of the study drug. Serious AE (SAE) was an AE resulting in any of the following outcomes: death; life-threatening adverse event, required hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, or a medically important event.
Time frame: Up to Day 15
Population: Analysis was performed on safety population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: 4 mg/kg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events | Any TEAE | 2 Participants |
| Cohort 1: 4 mg/kg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events | Any SAE | 0 Participants |
| Cohort 2: 8 mg/kg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events | Any TEAE | 3 Participants |
| Cohort 2: 8 mg/kg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events | Any SAE | 0 Participants |
Secondary
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to 48 Hour Post Dose Time Point (AUC0-48) of OP-101
Area under the concentration versus time curve from time zero to 48 hour post dose time point.
Time frame: Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose
Population: Analysis was performed on PK parameter population.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1: 4 mg/kg | Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to 48 Hour Post Dose Time Point (AUC0-48) of OP-101 | 121.705 hr*mcg/mL | Standard Deviation 16.9069 |
| Cohort 2: 8 mg/kg | Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to 48 Hour Post Dose Time Point (AUC0-48) of OP-101 | 222.173 hr*mcg/mL | Standard Deviation 12.469 |
Secondary
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of OP-101
AUC0-last: Area under the concentration versus time curve from time zero to the last quantifiable concentration (Clast).
Time frame: Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose
Population: Analysis was performed on PK parameter population.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1: 4 mg/kg | Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of OP-101 | 80.940 hr*mcg/mL | Standard Deviation 51.819 |
| Cohort 2: 8 mg/kg | Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to the Last Quantifiable Concentration (AUC0-last) of OP-101 | 212.325 hr*mcg/mL | Standard Deviation 30.6459 |
Secondary
Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of OP-101
Cmax: maximum observed plasma concentration.
Time frame: Pre-dose, 0.5 hours and 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose
Population: Analysis was performed on pharmacokinetic (PK) parameter population which was defined as all participants who received a dose of study drug and had at least 1 PK parameter.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1: 4 mg/kg | Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of OP-101 | 3.473 microgram per milliliter(mcg/mL) | Standard Deviation 0.8183 |
| Cohort 2: 8 mg/kg | Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of OP-101 | 6.640 microgram per milliliter(mcg/mL) | Standard Deviation 0.6073 |
Secondary
Pharmacokinetics: Renal Clearance (CLR) for OP-101
CLR was defined as renal clearance of the drug from plasma utilizing the AUC and cumulative amount of unchanged study drug excreted into the urine (Ae) to the same duration (as Amount recovered/AUC at 0-48 hours).
Time frame: Pre-dose, 0 to 4, 4 to 8, 8 to 12, 12 to 18, 18 to 24, and 24 to 48 hours post dose
Population: Analysis was performed on PK parameter population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1: 4 mg/kg | Pharmacokinetics: Renal Clearance (CLR) for OP-101 | 0.175 liter per hour (L/hr) | Standard Deviation 0.0354 |
| Cohort 2: 8 mg/kg | Pharmacokinetics: Renal Clearance (CLR) for OP-101 | 0.150 liter per hour (L/hr) | Standard Deviation 0.0606 |
Secondary
Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of OP-101
Tmax: time to reach maximum observed plasma concentration.
Time frame: Pre-dose, 0.5 hours and at 1, 2, 4, 6, 8, 10, 12, 16, 24, 30-36, 48 hours post-dose
Population: Analysis was performed on PK parameter population.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1: 4 mg/kg | Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of OP-101 | 14.015 hours |
| Cohort 2: 8 mg/kg | Pharmacokinetics: Time to Reach Maximum Plasma Concentration (Tmax) of OP-101 | 16.000 hours |